| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.
|
J Infect Dis
|
2005
|
3.52
|
|
2
|
Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2006
|
1.96
|
|
3
|
Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection.
|
Expert Opin Pharmacother
|
2012
|
1.95
|
|
4
|
High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists.
|
J Antimicrob Chemother
|
2010
|
1.94
|
|
5
|
Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania.
|
Clin Infect Dis
|
2009
|
1.92
|
|
6
|
Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes.
|
J Clin Microbiol
|
2008
|
1.81
|
|
7
|
Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.
|
J Clin Microbiol
|
2005
|
1.75
|
|
8
|
Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests.
|
J Clin Microbiol
|
2009
|
1.67
|
|
9
|
High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
|
AIDS
|
2007
|
1.62
|
|
10
|
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach.
|
Retrovirology
|
2009
|
1.58
|
|
11
|
HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C.
|
J Antimicrob Chemother
|
2008
|
1.52
|
|
12
|
Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy.
|
AIDS
|
2014
|
1.51
|
|
13
|
Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbott real-time viral load assay.
|
J Clin Microbiol
|
2011
|
1.42
|
|
14
|
Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola.
|
J Antimicrob Chemother
|
2008
|
1.42
|
|
15
|
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy.
|
AIDS
|
2006
|
1.37
|
|
16
|
Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses.
|
J Virol Methods
|
2006
|
1.31
|
|
17
|
Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
|
J Antimicrob Chemother
|
2007
|
1.27
|
|
18
|
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.
|
J Acquir Immune Defic Syndr
|
2006
|
1.27
|
|
19
|
Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools.
|
J Med Virol
|
2009
|
1.25
|
|
20
|
Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.
|
Antimicrob Agents Chemother
|
2012
|
1.24
|
|
21
|
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003.
|
J Acquir Immune Defic Syndr
|
2005
|
1.14
|
|
22
|
Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions.
|
J Infect Dis
|
2009
|
1.12
|
|
23
|
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
|
AIDS
|
2013
|
1.10
|
|
24
|
Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.
|
AIDS
|
2008
|
1.09
|
|
25
|
Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network.
|
Clin Infect Dis
|
2012
|
1.05
|
|
26
|
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
|
J Antimicrob Chemother
|
2007
|
1.05
|
|
27
|
Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity.
|
HIV Clin Trials
|
2005
|
1.04
|
|
28
|
Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements.
|
J Antimicrob Chemother
|
2008
|
1.03
|
|
29
|
Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors.
|
J Antimicrob Chemother
|
2007
|
1.02
|
|
30
|
Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain.
|
J Med Virol
|
2006
|
0.99
|
|
31
|
Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients.
|
J Clin Microbiol
|
2003
|
0.98
|
|
32
|
Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance.
|
J Clin Virol
|
2010
|
0.98
|
|
33
|
Hepatitis C therapy with HCV NS5B polymerase inhibitors.
|
Expert Opin Pharmacother
|
2013
|
0.98
|
|
34
|
High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor.
|
AIDS
|
2010
|
0.97
|
|
35
|
Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
|
AIDS
|
2010
|
0.96
|
|
36
|
Raltegravir and etravirine are active against HIV type 1 group O.
|
AIDS Res Hum Retroviruses
|
2009
|
0.94
|
|
37
|
Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.
|
AIDS Res Hum Retroviruses
|
2011
|
0.94
|
|
38
|
Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain.
|
Virol J
|
2012
|
0.94
|
|
39
|
Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals.
|
J Virol Methods
|
2004
|
0.92
|
|
40
|
Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.
|
AIDS
|
2008
|
0.92
|
|
41
|
Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.
|
AIDS
|
2004
|
0.91
|
|
42
|
Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms.
|
Clin Infect Dis
|
2012
|
0.90
|
|
43
|
Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment naïve HIV-infected individuals (CoRIS).
|
Antiviral Res
|
2011
|
0.90
|
|
44
|
Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C.
|
Antivir Ther
|
2013
|
0.90
|
|
45
|
Genetic mechanisms of resistance to NRTI and NNRTI.
|
HIV Clin Trials
|
2002
|
0.90
|
|
46
|
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.
|
AIDS Res Hum Retroviruses
|
2007
|
0.89
|
|
47
|
Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
|
Antivir Ther
|
2007
|
0.89
|
|
48
|
Molecular surveillance of HIV-1 in Madrid, Spain: a phylogeographic analysis.
|
J Virol
|
2011
|
0.89
|
|
49
|
Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients.
|
Antivir Ther
|
2011
|
0.89
|
|
50
|
Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.
|
Antiviral Res
|
2011
|
0.88
|
|
51
|
Hepatitis B, C, and D and HIV infections among immigrants from Equatorial Guinea living in Spain.
|
Am J Trop Med Hyg
|
2013
|
0.88
|
|
52
|
Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
|
J Med Virol
|
2005
|
0.87
|
|
53
|
Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
|
J Med Virol
|
2005
|
0.87
|
|
54
|
Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database.
|
AIDS
|
2010
|
0.87
|
|
55
|
Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
|
J Antimicrob Chemother
|
2010
|
0.86
|
|
56
|
Drug resistance mutations in patients infected with HIV-2 living in Spain.
|
J Antimicrob Chemother
|
2011
|
0.86
|
|
57
|
Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy.
|
J Med Virol
|
2007
|
0.86
|
|
58
|
Antiviral effect of raltegravir on HTLV-1 carriers.
|
J Antimicrob Chemother
|
2011
|
0.86
|
|
59
|
Drug interactions with new hepatitis C oral drugs.
|
Expert Opin Drug Metab Toxicol
|
2015
|
0.86
|
|
60
|
Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain.
|
Liver Int
|
2013
|
0.85
|
|
61
|
HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 Genotyping System.
|
J Antimicrob Chemother
|
2010
|
0.85
|
|
62
|
Prevalence of G333D/E in naive and pretreated HIV-infected patients.
|
AIDS Res Hum Retroviruses
|
2002
|
0.85
|
|
63
|
Changing rate of non-B subtypes and coinfection with hepatitis B/C viruses in newly diagnosed HIV type 1 individuals in Spain.
|
AIDS Res Hum Retroviruses
|
2010
|
0.84
|
|
64
|
Pharmacogenetics of antiretroviral therapy.
|
Expert Opin Drug Metab Toxicol
|
2014
|
0.84
|
|
65
|
Treatment response and drug resistance in patients infected with HIV type 1 group O viruses.
|
AIDS Res Hum Retroviruses
|
2005
|
0.84
|
|
66
|
Prevalence of HTLV-1/2 infections in Spain: A cross-sectional hospital-based survey.
|
AIDS Res Hum Retroviruses
|
2010
|
0.82
|
|
67
|
Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.
|
Antivir Ther
|
2011
|
0.81
|
|
68
|
Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.
|
HIV Clin Trials
|
2003
|
0.81
|
|
69
|
Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients.
|
J Clin Microbiol
|
2003
|
0.81
|
|
70
|
Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir.
|
AIDS
|
2012
|
0.81
|
|
71
|
X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain.
|
AIDS
|
2014
|
0.81
|
|
72
|
Genetic mechanisms of resistance to protease inhibitors and entry inhibitors.
|
HIV Clin Trials
|
2002
|
0.80
|
|
73
|
Hepatitis C cure with antiviral therapy - benefits beyond the liver.
|
Antivir Ther
|
2015
|
0.80
|
|
74
|
Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.
|
Antimicrob Agents Chemother
|
2010
|
0.80
|
|
75
|
Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.
|
Med Sci Monit
|
2002
|
0.80
|
|
76
|
Management and treatment of chronic hepatitis B in HIV-positive patients.
|
Ann Med
|
2014
|
0.80
|
|
77
|
Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients.
|
Clin Infect Dis
|
2014
|
0.79
|
|
78
|
Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
|
Retrovirology
|
2012
|
0.79
|
|
79
|
Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.
|
Expert Opin Drug Saf
|
2015
|
0.79
|
|
80
|
Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.
|
Int J Antimicrob Agents
|
2002
|
0.79
|
|
81
|
HTLV infection among foreign pregnant women living in Spain.
|
J Clin Virol
|
2011
|
0.79
|
|
82
|
[Resistance to integrase inhibitors].
|
Enferm Infecc Microbiol Clin
|
2008
|
0.79
|
|
83
|
Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy.
|
J Clin Virol
|
2013
|
0.79
|
|
84
|
Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure.
|
AIDS Res Hum Retroviruses
|
2003
|
0.79
|
|
85
|
Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
|
Antivir Ther
|
2014
|
0.79
|
|
86
|
Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption.
|
Clin Infect Dis
|
2005
|
0.78
|
|
87
|
Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.
|
Antivir Ther
|
2014
|
0.78
|
|
88
|
Emerging challenges in managing hepatitis B in HIV patients.
|
Curr HIV/AIDS Rep
|
2015
|
0.78
|
|
89
|
[Socio-demographic factors associated with the progression of HIV infection and the impact of HAART in a seroconverter cohort in Madrid (1986-2009)].
|
Enferm Infecc Microbiol Clin
|
2011
|
0.78
|
|
90
|
New therapeutic strategies for raltegravir.
|
J Antimicrob Chemother
|
2009
|
0.78
|
|
91
|
Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes.
|
J Antimicrob Chemother
|
2013
|
0.78
|
|
92
|
Association between HLA alleles and HAM/TSP in individuals infected with HTLV-1.
|
J Neurol
|
2013
|
0.78
|
|
93
|
Association between tipranavir plasma levels and virological response in HIV-infected patients.
|
AIDS Res Hum Retroviruses
|
2008
|
0.78
|
|
94
|
Prevalence of xenotropic murine leukemia virus-related virus infection in different risk populations in Spain.
|
AIDS Res Hum Retroviruses
|
2012
|
0.78
|
|
95
|
Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.
|
Antivir Ther
|
2007
|
0.77
|
|
96
|
Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.
|
AIDS Patient Care STDS
|
2004
|
0.77
|
|
97
|
Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.
|
AIDS Res Hum Retroviruses
|
2009
|
0.77
|
|
98
|
Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.
|
BMC Infect Dis
|
2007
|
0.77
|
|
99
|
Can drug resistance mutations influence the measurement of plasma HIV-RNA by different viral load techniques?
|
AIDS Patient Care STDS
|
2003
|
0.77
|
|
100
|
Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
|
Antivir Ther
|
2014
|
0.77
|
|
101
|
Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.
|
AIDS Res Hum Retroviruses
|
2006
|
0.77
|
|
102
|
Very late HCV relapse following triple therapy for hepatitis C.
|
Antivir Ther
|
2014
|
0.77
|
|
103
|
Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis.
|
Antivir Ther
|
2015
|
0.76
|
|
104
|
Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.
|
Clin Infect Dis
|
2002
|
0.75
|
|
105
|
Spontaneous hepatitis C virus clearance in one HIV patient with chronic hepatitis C bearing IL28B-CC alleles and detectable plasma HIV-RNA.
|
AIDS
|
2014
|
0.75
|
|
106
|
Advances in treating drug-resistant hepatitis B virus in HIV-infected patients.
|
Expert Opin Pharmacother
|
2014
|
0.75
|
|
107
|
Molecular epidemiology and clinical features of human T cell lymphotropic virus type 1 infection in Spain.
|
AIDS Res Hum Retroviruses
|
2014
|
0.75
|
|
108
|
Short communication: RNASEL alleles and susceptibility to infection by human retroviruses and hepatitis viruses.
|
AIDS Res Hum Retroviruses
|
2012
|
0.75
|
|
109
|
Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations.
|
AIDS
|
2003
|
0.75
|
|
110
|
Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
|
Antivir Ther
|
2013
|
0.75
|
|
111
|
Transmission of HIV type 1 through blood transfusion from an antibody-negative/p24 antigen-negative donor.
|
AIDS Res Hum Retroviruses
|
2003
|
0.75
|
|
112
|
Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: implications for tipranavir use.
|
AIDS Patient Care STDS
|
2005
|
0.75
|
|
113
|
Low rate of HIV-1 codon 215 revertants in antiretroviral-experienced patients.
|
AIDS
|
2003
|
0.75
|
|
114
|
Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials.
|
J Antimicrob Chemother
|
2007
|
0.75
|
|
115
|
[HIV superinfection: clinical and biological implications].
|
Med Clin (Barc)
|
2003
|
0.75
|
|
116
|
Do integrase inhibitors impact on the HIV reservoir.
|
AIDS Rev
|
2011
|
0.75
|
|
117
|
Prevalence of drug resistance genotypes causing broad cross-resistance to nucleos(t)ide analogues.
|
AIDS
|
2004
|
0.75
|